Federal Cannabis Legalization turns 50 this year—if you start counting from 1975, when decriminalization first splashed across a handful of progressive states before stalling for two decades. Half a century later, marijuana is still a Schedule I controlled substance, legally equated with heroin and LSD. That stubborn classification blocks research, inflates taxes under Internal Revenue Code § 280E, and ghettoizes multi-billion-dollar businesses outside ordinary banking.
You’ve heard the drumbeat of change: Health & Human Services (HHS) recommended moving cannabis to Schedule III in 2023; the Drug Enforcement Administration (DEA) opened a rule-making docket in 2024; and newly re-elected President Donald Trump re-installed career prohibitionist Derek Maltz as acting administrator. Yet as of April 2025 the DEA’s administrative law judge still has no briefing schedule on the proposal, effectively grinding the process to a halt. Cannabis Business TimesNational Law Review
Below, we unpack why rescheduling—even if it happens—will not equal federal “legalization,” what it would change, and where the real bottlenecks sit. Then we outline a pragmatic playbook for operators, investors, and advocates who can’t afford to wait for Washington to get its act together.
The 50-Year Stalemate: Déjà Vu in Cannabis Policy
-
Politics, not pharmacology, keeps marijuana in Schedule I. Congress embedded cannabis at the very top of the Controlled Substances Act (CSA) in 1970 as a placeholder pending scientific review. The review never arrived; the placeholder became doctrine.
-
In 1971, astronomer Carl Sagan called the illegality “outrageous.” In 2025, the quote still lands because the statute still stands.
-
As of today, 24 states allow adult-use sales and 37 states operate medical programs, yet federal law disclaims any accepted medical use.
What Moving to Schedule III Would—and Would Not—Do
| What Changes | What Stays the Same | |
|---|---|---|
| Taxes | § 280E vanishes for cannabis businesses, allowing ordinary deductions. | State-level gross-receipts & excise taxes persist. |
| Research | Schedule III unlocks streamlined DEA research licenses. | FDA still treats cannabis as an unapproved drug. |
| Banking | Marginally easier for national banks wary of “proceeds of criminal activity.” | FinCEN guidance unchanged; SAFE Banking Act still needed. |
| Interstate Commerce | None—shipping Schedule III drugs across state lines without FDA approval remains illegal. | The FDCA’s drug-exclusion rule blocks interstate sales of THC or CBD products without New Drug Applications. |
Bottom line: Rescheduling removes some shackles yet keeps the industry fenced inside the CSA and the Food, Drug & Cosmetic Act (FDCA). FDA Law Blog
The FDA Wall Nobody Talks About
Even if DEA blesses Schedule III, the FDCA forbids marketing any “new drug” in interstate commerce until the agency signs off—and botanically derived THC or CBD count as drugs because both have been subjects of substantial clinical investigations (see Epidiolex® and Marinol®). FDA cannot simply waive those statutory mandates to magically make Federal Cannabis Legalization. Congress would have to carve out an exemption in the FDCA or enact a parallel overlay (think: Tobacco Control Act for nicotine). Until then, multi-state cannabis shipments remain theoretical.
Hemp and the “Drug Exclusion” Catch-22
The 2018 Farm Bill legalized hemp production (<0.3 % Δ<sub>9</sub>-THC), but it punted consumable products to FDA oversight. Today:
-
CBD food, beverages, and dietary supplements violate the FDCA’s drug-exclusion rule.
-
THCA flower exploits a labeling loophole, yet once burned it converts to Δ<sub>9</sub>-THC—a de facto Schedule I compound.
-
Enforcement is sporadic, giving Big Alcohol cover to sell “hemp drinks” that would never clear a pharmaceutical audit.
Without Congressional action harmonizing hemp-derived cannabinoids with the FDCA, the legal status of those SKUs remains—at best—murky.
SAFE Banking Act: Perpetual Bridesmaid
Since 2019 the Secure and Fair Enforcement Banking Act (SAFE) has cleared the House seven times but never reached a Senate floor vote, not even after being re-branded the SAFER Banking Act in 2023. In March 2025, Montana’s legislature felt compelled to pass a resolution begging Congress to move the bill. That tells you everything about its prospects. The Marijuana Herald
If lawmakers cannot pass a modest banking carve-out with broad bipartisan support, expecting them to engineer comprehensive cannabis reform—rewriting the CSA, FDCA, tax code, and international treaty reservations—verges on magical thinking.
Congress Is Still the Bottleneck
Full federal legalization would require:
-
Descheduling cannabis or creating a bespoke schedule.
-
Amending the FDCA to allow non-pharma cannabis products.
-
Tax overhaul beyond § 280E (e.g., an excise structure akin to alcohol or tobacco).
-
Regulatory authority—either empowering FDA/TTB or establishing a new Cannabis Bureau.
-
International treaty compliance, likely through a caveat similar to Canada’s dual-track system.
None of that fits into a continuing-resolution rider; it needs standalone legislation and a filibuster-proof path. The 118th and 119th Congresses have not introduced anything remotely that ambitious.
Industry Outlook: 2025 Challenges Beyond Scheduling
Even optimistic analysts forecast $50 billion in U.S. cannabis sales in 2025, yet Federal Cannabis Legalization faces tightening capital, aggressive consolidation, and competitive pressure from alcohol, tobacco, and pharmaceutical incumbents. Investopedia
A quick pulse check for operators:
-
Margins remain razor-thin where wholesale prices are falling (California, Oregon) or vertically integrated monopolies dominate (Florida, New York).
-
State-level rule changes—potency caps, environmental standards, social-equity mandates—arrive faster than software updates.
-
Insurance, payroll, and merchant processing still treat plant-touching businesses as radioactive, despite FinCEN guidance.
In short, rescheduling helps, but it does not cure these structural headwinds.
Practical Playbook for Federal Cannabis Legalization in 2025
-
Optimize for State Compliance First
-
Treat each state as its own country; what works in Illinois will not fly in Alabama.
-
Maintain a regulatory horizon scan for pending rule-making and ballot initiatives.
-
Build internal SOPs that exceed state minimums—auditors love paperwork.
-
-
Engineer 280E Exit Scenarios (Contingent on Schedule III)
-
Map your chart of accounts now so ordinary deductions spring to life the moment the DEA rule publishes.
-
If you have dormant IP or ancillary service entities, model whether migrating assets unlocks operating-expense deductions.
-
-
Banking Work-Arounds
-
Tier-two and credit-union relationships remain the fastest path to compliant depository services.
-
Push vendors toward FedNow rails or blockchain B2B solutions to reduce armored-car fees.
-
-
Hemp & THCA Risk Mitigation
-
Separate hemp supply chains from THC operations; silo your packaging, SOPs, and customer-acquisition funnels.
-
Adopt third-party testing protocols that track total potential THC (Δ<sub>9</sub> + THCA × 0.877) to pre-empt enforcement.
-
-
Advocacy ROI
-
Align with multi-state coalitions focused on FDCA carve-outs for consumable cannabinoids.
-
Fund targeted lobbying for SAFE Banking—small progress beats grand illusions.
-
Key Takeaways
-
Rescheduling ≠ legalization. Schedule III would remove the 280E tax straitjacket and ease research barriers but leave interstate commerce, FDA approval, and banking gaps unresolved. Independent Voter NewsFDA Law Blog
-
Congress remains the gatekeeper. If lawmakers cannot pass SAFE Banking after six years, expecting full descheduling in the near term is unrealistic. WikipediaThe Marijuana Herald
-
Hemp regulation is the hidden iceberg. Drug-exclusion rules freeze CBD/THC consumables out of legitimate channels, inviting grey-market competition and regulatory whiplash.
-
Operators must plan around the status quo. Nail state compliance, restructure for potential 280E relief, and hedge hemp exposure while pushing for incremental federal reforms.
-
Stay politically active. Local victories—decriminalization, licensing caps, tax relief—continue to outpace federal movement, and they shape day-to-day profitability more than any D.C. headline.
Final Word—and a Next Step
Federal reform is a marathon on a treadmill: lots of effort, painfully little forward motion. Smart businesses thrive anyway by adapting to the rules that exist, not the ones we wish for. When Congress finally takes a meaningful swing—be it SAFE Banking, FDCA reform, or full descheduling—operators who prepared today will capture tomorrow’s upside.
Ready to audit your compliance strategy, restructure for post-280E reality, or draft comments for the DEA rescheduling docket? Contact the Cannabis Industry Lawyer team to schedule a consultation. We’ve spent the last decade in the trenches so you don’t have to—and we plan to stick around until lawmakers catch up.
Nothing in this article constitutes legal advice; consult counsel licensed in your jurisdiction.
